ESMO 2026 Preview: Seven of Twelve Presidential Abstracts Have Already Claimed a Survival Win
Direction is known for ten of twelve Presidential readouts. Size is sealed, and ADCs face the survival test again.
Coverage
ADCs Returned 0.46 in Relapsed Disease and 1.15 in the Front Line at WCLC
The dividing line is not the target or the payload. It is the setting: relapsed disease against chemotherapy, or the front line against chemo-IO.
The ADC Decade Accelerates: What to Watch at ASCO 2026
The antibody–drug conjugate field arrives at ASCO 2026 in a fundamentally different shape. This Synopulse pre-conference briefing maps the five catalysts, 16+ assets, and strategic themes that will reshape the competitive landscape.